tetano
Editor, Senior Moderator
NPJ Vaccines
. 2021 Mar 30;6(1):47.
doi: 10.1038/s41541-021-00321-8.
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
Qingmei Jia[SUP] 1 [/SUP], Helle Bielefeldt-Ohmann[SUP] 2 [/SUP], Rachel M Maison[SUP] 3 [/SUP], Sa?a Masle?a-Gali?[SUP] 1 [/SUP], Sarah K Cooper[SUP] 4 [/SUP], Richard A Bowen[SUP] 3 [/SUP], Marcus A Horwitz[SUP] 5 [/SUP]
Affiliations
Abstract
To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS ?capB vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins are constructed using the LVS ?capB vector, a highly attenuated replicating intracellular bacterium, and evaluated for efficacy in golden Syrian hamsters, which develop severe COVID-19-like disease. Hamsters immunized intradermally or intranasally with a vaccine co-expressing the Membrane and Nucleocapsid proteins and challenged 5 weeks later with a high dose of SARS-CoV-2 are protected against severe weight loss and lung pathology and show reduced viral loads in the oropharynx and lungs. Protection correlates with anti-Nucleocapsid antibody. This potent vaccine should be safe; inexpensive; easily manufactured, stored, and distributed; and given the high homology between Membrane and Nucleocapsid proteins of SARS-CoV and SARS-CoV-2, potentially serve as a universal vaccine against the SARS subset of pandemic causing ?-coronaviruses.
. 2021 Mar 30;6(1):47.
doi: 10.1038/s41541-021-00321-8.
Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
Qingmei Jia[SUP] 1 [/SUP], Helle Bielefeldt-Ohmann[SUP] 2 [/SUP], Rachel M Maison[SUP] 3 [/SUP], Sa?a Masle?a-Gali?[SUP] 1 [/SUP], Sarah K Cooper[SUP] 4 [/SUP], Richard A Bowen[SUP] 3 [/SUP], Marcus A Horwitz[SUP] 5 [/SUP]
Affiliations
- PMID: 33785745
- DOI: 10.1038/s41541-021-00321-8
Abstract
To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS ?capB vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins are constructed using the LVS ?capB vector, a highly attenuated replicating intracellular bacterium, and evaluated for efficacy in golden Syrian hamsters, which develop severe COVID-19-like disease. Hamsters immunized intradermally or intranasally with a vaccine co-expressing the Membrane and Nucleocapsid proteins and challenged 5 weeks later with a high dose of SARS-CoV-2 are protected against severe weight loss and lung pathology and show reduced viral loads in the oropharynx and lungs. Protection correlates with anti-Nucleocapsid antibody. This potent vaccine should be safe; inexpensive; easily manufactured, stored, and distributed; and given the high homology between Membrane and Nucleocapsid proteins of SARS-CoV and SARS-CoV-2, potentially serve as a universal vaccine against the SARS subset of pandemic causing ?-coronaviruses.